{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:22:51Z","timestamp":1740126171694,"version":"3.37.3"},"reference-count":27,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2013,3,4]],"date-time":"2013-03-04T00:00:00Z","timestamp":1362355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["30972602"],"award-info":[{"award-number":["30972602"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Education Bureau of Beijing","award":["KZ201210025024"],"award-info":[{"award-number":["KZ201210025024"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2013,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Telbivudine, one of the oral anti\u2010hepatitis B virus (<jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content>) nucleoside analogues, has been used for more than 5\u00a0years to treat <jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>eAg\u2010positive and \u2010negative chronic hepatitis B (CHB) patients. This includes not only global Phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content> trials, but also Chinese Phase <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content> trials and several real\u2010world clinical practice studies from China. The present review will first focus on 1\u2010, 2\u2010 and 3\u2010year data of telbivudine therapy on <jats:styled-content style=\"fixed-case\">HBV DNA<\/jats:styled-content> suppression, alanine aminotransferase (<jats:styled-content style=\"fixed-case\">ALT<\/jats:styled-content>) normalization, hepatitis B e antigen (<jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>eAg) seroconversion, viral resistance and safety in <jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>eAg\u2010positive and \u2010negative CHB patients. Second, telbivudine treatment predictors, including <jats:styled-content style=\"fixed-case\">HBV DNA<\/jats:styled-content> undetectability, <jats:styled-content style=\"fixed-case\">ALT<\/jats:styled-content> level and other immune\u2010related markers at 12 and 24\u00a0weeks will be summarized to optimize therapy. Besides several retrospective studies, the Chinese <jats:styled-content style=\"fixed-case\">EFFORT<\/jats:styled-content> prospective study adapted from telbivudine virological response at 24\u00a0weeks has shown very promising results. Finally, the Chinese experience of using telbivudine in the second and third trimesters of pregnancy to prevent perinatal transmission of HBV infection will be touched on citing the latest studies.<\/jats:p>","DOI":"10.1111\/jvh.12058","type":"journal-article","created":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T06:47:56Z","timestamp":1357022876000},"page":"3-8","source":"Crossref","is-referenced-by-count":3,"title":["Telbivudine treatment in chronic hepatitis <scp>B<\/scp>: experience from <scp>C<\/scp>hina"],"prefix":"10.1111","volume":"20","author":[{"given":"H.","family":"You","sequence":"first","affiliation":[{"name":"Liver Research Center Beijing Friendship Hospital Capital Medical University Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Jia","sequence":"additional","affiliation":[{"name":"Liver Research Center Beijing Friendship Hospital Capital Medical University Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,4]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066422"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.10.026"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02490.x"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-11-200712040-00183"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22075"},{"key":"e_1_2_11_7_1","first-page":"34","article-title":"Prolonged efficacy and safety of 3\u00a0years of continuous telbivudine treatment in Chinese chronic hepatitis B patients","volume":"3","author":"Jia J","year":"2009","journal-title":"Hepatol Int"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.11.018"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.12.019"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2007.05.004"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2010.01274.x"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.02.032"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.01.019"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043470"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)17701-0"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020681"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051285"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802878"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2009.01145.x"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1758"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23905"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22419"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.10.020"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1813"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.06.007"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.2003.00440.x"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1086\/514610"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(97)00080-7"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12058","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12058","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.12058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T21:13:14Z","timestamp":1694639594000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.12058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,4]]},"references-count":27,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["10.1111\/jvh.12058"],"URL":"https:\/\/doi.org\/10.1111\/jvh.12058","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"type":"print","value":"1352-0504"},{"type":"electronic","value":"1365-2893"}],"subject":[],"published":{"date-parts":[[2013,3,4]]}}}